TCF7L2 and cardiac hypertrophy: This research demonstrated that EMPA attenuates the progressive TAC-induced cardiac hypertrophy by directly binding to FZD to inhibit the Wnt/β-catenin/TCF7L2 signaling in cardiomyocytes, thereby protecting the heart from progressive HF.